Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Inventories, Finished Goods: ¥0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600521 Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
88 GF Score
Price ¥15.97
GF Value ¥17.13
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Huahai Pharmaceutical Co Inventories, Finished Goods?

Zhejiang Huahai Pharmaceutical Co SHSE:600521 -1.42% 88 Inventories, Finished Goods is ¥0 Mil as of Jun. 2026. GuruFocus rates SHSE:600521 with a GF Score™ of 88/100 and a GF Value™ of ¥17.13 (Fairly Valued). The stock has 8 warning signs investors should review.

Zhejiang Huahai Pharmaceutical Co's quarterly finished goods declined from Dec. 2025 (¥2,216 Mil) to Mar. 2026 (¥0 Mil) but then stayed the same from Mar. 2026 (¥0 Mil) to Jun. 2026 (¥0 Mil).

Zhejiang Huahai Pharmaceutical Co's annual finished goods declined from Dec. 2023 (¥2,096 Mil) to Dec. 2024 (¥1,984 Mil) but then increased from Dec. 2024 (¥1,984 Mil) to Dec. 2025 (¥2,216 Mil).

Zhejiang Huahai Pharmaceutical Co Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Zhejiang Huahai Pharmaceutical Co's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Huahai Pharmaceutical Co Inventories, Finished Goods Chart

Zhejiang Huahai Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,420.16 1,867.62 2,095.63 1,984.01 2,216.45

Zhejiang Huahai Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,085.66 0.00 2,216.45 0.00 0.00
SHSE:600521
88GF Score
Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Huahai Pharmaceutical Co Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ¥0 Mil mean?
Zhejiang Huahai Pharmaceutical Co (SHSE:600521) has a Inventories, Finished Goods of ¥0 Mil as of Jun. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Zhejiang Huahai Pharmaceutical Co and its competitors.
Is Zhejiang Huahai Pharmaceutical Co's Inventories, Finished Goods too high?
Zhejiang Huahai Pharmaceutical Co's current Inventories, Finished Goods is ¥0 Mil. Overall, Zhejiang Huahai Pharmaceutical Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Huahai Pharmaceutical Co's Inventories, Finished Goods compare to ZTS?
Zhejiang Huahai Pharmaceutical Co's Inventories, Finished Goods of ¥0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Zhejiang Huahai Pharmaceutical Co and its competitors. Zhejiang Huahai Pharmaceutical Co's current Inventories, Finished Goods is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Huahai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co (SHSE:600521) is currently considered Fairly Valued. The stock's GF Value™ is ¥17.13, compared to a current price of ¥15.97 — trading 6.8% below its estimated fair value. The current Inventories, Finished Goods is ¥0 Mil. Zhejiang Huahai Pharmaceutical Co's overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Zhejiang Huahai Pharmaceutical Co (SHSE:600521), the current Inventories, Finished Goods is ¥0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥15.97 is trading 6.8% below its estimated GF Value™ of ¥17.13. GuruFocus considers Zhejiang Huahai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600521:

  • Inventories, Finished Goods: ¥0 Mil
  • GF Value™: ¥17.13 vs. price of ¥15.97 (6.8% below fair value)
  • GF Score™: 88/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Huahai Pharmaceutical Co Business Description

Address Xunqiao, Zhejiang Province, Linhai, CHN, 317024
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
88GF Score

Get the complete analysis for SHSE:600521

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.97
Price
¥17.13
GF Value